MAPK Pathway Gene Mutation clinical trials at UCSF

1 research study open to eligible people

A MAPK pathway gene mutation is a change in genes that control cell growth and division. UCSF is running an early phase study of an oral drug for people with solid tumors and MAPK gene changes. The study describes safety, dosing, and how the body processes the medicine.

Showing trials for

  • NST-628 Oral Tablets in Subjects With Solid Tumors

    open to eligible people ages 18 years and up

    This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment options.

    San Francisco, California and other locations

Our lead scientists for MAPK Pathway Gene Mutation research studies include .

Last updated: